Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

CStone China

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
Website:
www.cstonepharma.com
Looking for
Ping Zhao
Greater China General Manager and Head of Commercial Operations 
Functionality
Management

CUBIC INC United States

CUBIC is the ultimate platform for emerging and growing companies seeking to expand their market to China or establish a business presence in China through various services and programs fitting every clients' needs and stage. When vacationing abroad, your best guide is a native, and business is no different. As CUBIC is owned by one of the largest Chinese incubator Thinkzone, you can be confident that you will be benefiting from one of the most extensive and influential networks in China.
Website:
www.cubic-boston.com
Looking for
Headquartner in China
Yes
Lejia Caro
Business Development 
Functionality
Business Development

Curevo Vaccine United States

Curevo is a clinical stage company dedicated to bringing next generation vaccines that offer effectiveness, safety, tolerability, and production advantages to the market, quickly and efficiently.
Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development.
Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available.
Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research and GC Pharma.
Curevo's lead product, a Zoster (Shingles) Vaccine, has completed Phase I and shown promising results. We are targeting a unique position in the $20B (by 2030) Varicella Zoster Virus vaccine market.
Website:
www.curevovaccine.com
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Looking for
Funding Status
Raising Series-A
Headquartner in China
No
Plan in China
As a premium and high margin segment, the shingles vaccine market represents a significant opportunity for local, regional, or global players.
George Simeon
CEO 
Functionality
Management

Curon Biopharma China

Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies. It completed a $150 million USD Series A financing led by 6 Dimensions Capital, Boyu Capital, and Temasek. With its internationally experienced senior executive management team, Curon Biopharma currently holds multiple promising novel cancer immuno-therapeutic agents in its pipeline and is committed to bring next generation cancer immunotherapies to patients. Curon strives to accelerate its pipeline assets clinical development, further expand its portfolio through in-licensing and other forms of collaboration with biotech and pharmaceutical companies around the world to bring more effective treatment options to patients.
Website:
curonbiopharma.com
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Looking for
Funding Status
Series A completed
Headquartner in China
Yes
Natasha Qin
商务拓展总监 
Functionality
Business Development

D2M Biotherapeutics United States

A human-genetics driven next generation immunity-oncology company
Website:
www.d2mbio.com
Looking for
Headquartner in China
No
Nan Bing
CEO 
Functionality
Management

Daiichi Sankyo Japan

Weiyong Sun
Senior Director 

Dawn Biopharmaceuticals Inc. United States

Dawn Biopharmaceuticals Inc (DBI) is a US firm founded by Gordon Lee, MD (UK MBChB), MBA (Wharton) who has access to a proprietary cell-based immunotherapeutic product for clinical development in the US. The product is a multivalent cancer therapy that integrates multiple anti-cancer mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses a therapeutic cytokine in the cancer - but not systemically.

(Please note that the website is pending.)

Website:
dawnbio.net
Company Size (Fulltime employees)
1-10
Year of foundation
2020
Looking for
Please specify your partnering goal
Strategic pharmaceutical or capital partner to accompany into Pre-IND and clinical trials.
Funding Status
Initial round
Headquartner in China
No
Plan in China
Open to partnerships with Chinese firms that have a proprietary small molecule or biodrug that could be encoded into our platform with the benefits of wider scope of applications, tumor-centric molecular therapeutic delivery, avoidance of peripheral (extra tumoral) actions and effects, and vectoring of high payload(s) for multi-arming.
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Gordon Lee
Founder 
Functionality
Management

Deutsche Bank AG London United Kingdom

Deutsche Bank is the largest bank in Germany and one of only 4 Depositary Receipt banks able to list Life Sciences and Medtech companies on US exchanges using ADRs.
Website:
www.dbadr.com
Company Size (Fulltime employees)
5000+
Year of foundation
1886
Looking for
Please specify your partnering goal
Meet companies hoping to list and raise capital in the US
Headquartner in China
No
Joseph Oakenfold
Vice President 
Functionality
Business Development

DIMITAR DIMITROV Bulgaria

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET

Website:
http://micar21.com/
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Please specify your partnering goal
Drug Discovery
Funding Status
raising
Now raising (In USD)
2500000
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Investment Focus
Oncology project
Slides Deck
(pdf, 939.67KB)
CEO 
Functionality
Management

DivaOra Group Russia

Manufacturing, whole sale innovation product EYEIMPROVER.com - the stimulator for the eyes
Website:
www.eyeimrpver.com
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Funding Status
investment, strategy investor
Headquartner in China
No
Plan in China
We want move our business from CHINA. We searshin investment and we are ready for relocation.
Olga Oshurkova
CEO & Owner 
Functionality
Management